Abstract:Objective: This research aimed to study the expression of PRDX6 mRNA in hepatocellular carcinoma (HCC) and its effect on the prognosis of HCC. Moreover, the effect of PRDX6 gene knockdown on the proliferation, migration, and invasion of HepG2 cells mediated by lentivirus was also examined. This study offers a theoretical and experimental basis for further research on the mechanism of PRDX6 in liver cancer and new methods for clinical diagnosis and treatment. Methods: RNA sequence data of 369 HCC patients were screened through the TCGA database, and the expression and clinical characteristics of PRDX6 mRNA were analyzed based on high- -throughput RNA sequencing data. HepG2 cells were divided into WT, sh-NC and sh- PRDX6 groups. Real-time PCR and Western blot were used to detect the expression levels of the PRDX6 gene and protein, respectively. CCK8 method was used to detect the proliferation activity of Hep- G2 cells, scratch healing test was used to detect the migration ability, Transwell chamber was used to detect the invasion ability, and Western blot was used to detect the expression levels of PI3K/Akt/mTOR signaling pathway and Notch signaling pathway-related proteins. Results: The expression of PRDX6 was significantly correlated with the gender, race, clinical stage, histological grade, and survival time of HCC patients ( P < 0.05). Compared with that in WT and sh-NC groups, the expression level of PRDX6 protein in HCC patients was significantly lower ( P < 0.01), the proliferation activity of HCC cells was significantly decreased ( P < 0.05), and the migration and invasion ability was significantly decreased ( P < 0.05) in the sh- PRDX6 group. The expression levels of PI3K, p-Akt, p-mTOR, Notch1, and Hes1 proteins in the sh- PRDX6 group were significantly lower than those in WT and sh-NC groups ( P < 0.05). Conclusion: The expression of PRDX6 may be closely related to the prognosis of HCC. Lentivirus- mediated PRDX6 knockdown can inhibit the proliferation, migration and invasion of HCC cells, which may be related to its regulating the PI3K/Akt/mTOR and Notch1 signaling pathways. PRDX6 is expected to be a new target for the diagnosis and treatment of liver cancer.

PRDX1 Influences the Occurrence and Progression of Liver Cancer by Inhibiting Mitochondrial Apoptosis Pathway.

Silencing PRDX3 Inhibits Growth and Promotes Invasion and Extracellular Matrix Degradation in Hepatocellular Carcinoma Cells

Peroxiredoxin 1, Restraining Cell Migration And Invasion, Is Involved In Hepatocellular Carcinoma Recurrence

Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.

Peroxiredoxin 1 modulates oxidative stress resistance and cell apoptosis through stemness in liver cancer under non-thermal plasma treatment

Diagnostic and Prognostic Significance of Peroxiredoxin 1 Expression in Human Hepatocellular Carcinoma

The Phospholipase A2 Activity of Peroxiredoxin 6 Promotes Cancer Cell Death Induced by Tumor Necrosis Factor Alpha in Hepatocellular Carcinoma

Dual Role of PRDX1 in Redox-Regulation and Tumorigenesis: Past and Future.

Up-regulation of peroxiredoxin-1 promotes cell proliferation and metastasis and inhibits apoptosis in cervical cancer

Peroxiredoxin 5 protects HepG2 cells from ethyl β-carboline-3-carboxylate-induced cell death via ROS-dependent MAPK signalling pathways

Overexpression of Prdx1 in Hilar Cholangiocarcinoma: a Predictor for Recurrence and Prognosis.

Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the β-catenin/ID2 pathway

Analysis of the Expression of PRDX6 in Patients with Hepatocellular Carcinoma and its Effect on the Phenotype of Hepatocellular Carcinoma Cells

Therapeutic Inhibition of Phospholipase D1 Suppresses Hepatocellular Carcinoma.

Silencing of Peroxiredoxin 2 Suppresses Proliferation and Wnt/β-catenin Pathway, and Induces Senescence in Hepatocellular Carcinoma

FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production

Silencing of PRDX2 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells

&Lt;p>silencing of Peroxiredoxin 1 Inhibits the Proliferation of Esophageal Cancer Cells and Promotes Apoptosis by Inhibiting the Activity of the PI3K/AKT Pathway</p>

Downregulation of PRRX1 Via the P53-Dependent Signaling Pathway Predicts Poor Prognosis in Hepatocellular Carcinoma.

PRMT1 Integrates Immune Microenvironment and Fatty Acid Metabolism Response in Progression of Hepatocellular Carcinoma

Suppressing DRP1-mediated Mitochondrial Fission and Mitophagy Increases Mitochondrial Apoptosis of Hepatocellular Carcinoma Cells in the Setting of Hypoxia